LIMITX^™ Technology is intended to mitigate the risks associated with intentional or overdose.

Status

LTX-03, an immediate-release hydrocodone bitartrate with acetaminophen tablet, is our lead LIMITX^™ development program.

Previously, we have run three exploratory human pharmacokinetic studies and two animal studies. These studies demonstrated:

• Efficacious blood levels of drug at a single tablet dose
• Up to a 65% reduction of peak plasma concentrations of drug in overdose situations compared to currently marketed formulations.
• An association between Cmax and opioid induced respiratory depression and death.